hsCRP

Semaglutide’s Impact on Inflammation and Cardiovascular Risk in Overweight Patients: Insights from the SELECT Trial

In the SELECT trial, semaglutide significantly lowered hsCRP levels and major cardiovascular events in patients with established atherosclerotic cardiovascular disease and overweight or obesity, suggesting inflammation reduction as a possib